Nasal Sprays and Skin Patches: The Future of COVID-19 Vaccines

August, 2022

Nasal sprays and skin patches: the future of COVID-19 vaccines

On July 26, researchers, scientists, and medical professionals gathered for the White House Summit of the Future of COVID-19 vaccines. The FDA recently approved a bivalent booster shot to better target the BA.5 variant, which should be ready for the public by the fall, but this summit allowed for large-scale ideation for future COVID-19 vaccines, because as we have seen, the virus does not seem to be going away any time soon. Researchers suggest that it will take another two years for COVID-19 to become endemic. Dr. Fauci was present at this summit and stated that “the holy grail” of COVID-19 vaccines would “not only to protect against disease, but to protect against acquisition, and by acquisition, transmission.”

Dr. Akiko Iwasaki, professor of immunobiology at the Yale School of Medicine, presented the idea of a virus-fighting nasal spray. Its selling point? Providing mucosal immunity, which, in the context of COVID-19, protects the nasal cavity and lungs from pathogens from the outside environment. Our current vaccines focus on systemic rather than mucosal immunity: an injection of Pfizer, Moderna, or virtually any other COVID-19 vaccine currently on the market produces antibodies in one’s bloodstream that generates an immune response against the virus. While these injectable vaccines have proven to offer robust systemic immunity over the past two years, virus transmission is still a major issue. Dr. Iwasaki emphasized how a nasal spray would “stop the virus from spreading right at the border,” or, the nose. “This is akin to putting a guard outside of the house in order to patrol for invaders, compared to putting the guards in the hallway of a building in hope they would capture the invader,” she further explained. A nasal spray could reduce the risk of virus transmission, and some scientists are even considering using an intranasal vaccine in conjunction with an intramuscular vaccine to enhance systemic immunity with mucosal immunity.

Mark Prausnitz, chief scientific officer of Micron Biomedical, proposed another vaccine alternative—skin patches. These patches can be administered at home, and they do not have to be stored in freezer-like temperatures, making them more accessible to the public. Moreover, a recent study demonstrated that skin patches can produce a strong immune response against COVID-19 variants.

The University of Queensland partnered with the biotechnology company Vaxxas and applied Vaxxas’s high density microarray patch (HD-MAP) technology to the Hexapro SARS-CoV-2 spike vaccine. Researchers found that the vaccine patch was 11 times more effective at neutralizing COVID-19 variants than the current injection. Dr. Christopher McMillan of the University of Queensland explained that “the high-density microarray patch is a vaccine delivery patch that precisely delivers the vaccine into the layers of the skin which are rich in immune cells.” In addition, though the study only tested the Hexapro vaccine, he stated that “so far, every vaccine type [they] have tested through the patch, including subunit, DNA, inactivated virus and conjugate produces superior immune responses compared to traditional needle vaccination methods.”

Importantly, the current vaccines are still effective at reducing the severity of illness; the possibility of nasal sprays and skin patches does not diminish this fact. However, with the ever-clever variants circulating the country and infecting people (even those who are up-to-date on their vaccines), researchers are taking all possible solutions under consideration. This summit also served as a call to Congress to invest in these novel research ideas, so that educating the public, manufacturing, and testing could soon be underway.

Extension of test kit shelf life

Inspire Diagnostics understands and appreciates our clients’ concerns over test kits showing expiration dates that have passed. Please rest assured that these rapid antigen test kits remain valid, accurate and safe for your testing needs.

The United States Food and Drug Administration (FDA) has approved an extended shelf life for the Intrivo On/Go test kits used by Inspire Diagnostics. Please visit for the official notice of extension.

FDA removes N95 respirators from medical device shortage list, signaling sufficient supply

On August 26, the U.S. Food and Drug Administration announced the removal of N95 respirators from the agency’s medical device shortage list, signaling that demand or projected demand for this type of face protection device commonly used in health care settings no longer exceeds the supply.

This action is the result of increased domestic manufacturing of N95 respirators, as well as updates to the FDA’s supply chain assessment based on engagement with industry and federal stakeholders, and the Centers for Disease Control and Prevention’s National Institute for Occupational Safety and Health’s (NIOSH) approval of new disposable N95s and reusable respirators.

Discover why hundreds of school leaders trust Inspire Diagnostics. Visit us online or email us at

More insights: Explore our latest content and news.

Like what you see? If you received this email from a friend and want to get the next issue, subscribe now at the bottom of our homepage.